AstraZeneca PLC - American Depositary Shares (AZN)
69.93
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 29th, 8:56 AM EDT
Detailed Quote
Previous Close
69.93
Open
-
Bid
69.86
Ask
69.93
Day's Range
N/A - N/A
52 Week Range
61.24 - 87.68
Volume
267,852
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
2.100 (3.00%)
1 Month Average Volume
6,996,968
Chart
About AstraZeneca PLC - American Depositary Shares (AZN)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility. Read More
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.
